On May 7, Hansen Medical, Inc. (NASDAQ:HNSN), a global leader in intravascular robotics, reported recent business highlights and financial results for the first quarter of fiscal year 2014 ended March 31, 2014. Total revenue for the first quarter ended March 31, 2014 increased 25% to $3.7 million, compared to revenue of $3.0 million in the same period in 2013. The Company commercialized two robotic systems in the quarter (1 Magellan System and 1 Sensei System). The Company uses the term “commercialized” to refer to revenue-generating system transactions, including rental transactions. Hansen Medical, Inc. (NASDAQ:HNSN) weekly performance is -30.90%. On last trading day company shares ended up $1.23. Analysts mean target price for the company is $2.00. Hansen Medical, Inc. (NASDAQ:HNSN) distance from 50-day simple moving average (SMA50) is -45.16%.
TherapeuticsMD Inc (NASDAQ:TXMD) Director Tommy Thompson purchased 14,000 shares of TherapeuticsMD stock in a transaction dated Thursday, May 8th. The stock was purchased at an average cost of $3.57 per share, with a total value of $49,980.00. TherapeuticsMD Inc (NYSEMKT:TXMD) shares fell -1.03% in last trading session and ended the day on $3.83 . TXMD Gross Margin is 77.30% and its return on assets is -64.10%. TherapeuticsMD Inc (NYSEMKT:TXMD) quarterly performance is -36.59%.
Pacific Biosciences of California, Inc (NASDAQ:PACB) provider of the PacBio(R) RS II system, announced that its Single Molecule, Real-Time (SMRT(R)) DNA Sequencing technology will be featured in seven podium and 13 poster presentations at the 2014 American Society for Microbiology (ASM) annual meeting in Boston. Pacific Biosciences of California (NASDAQ:PACB) shares moved down -4.31% in last trading session and was closed at $4.44, while trading in range of $4.43 – $4.98. Pacific Biosciences of California (NASDAQ:PACB) year to date (YTD) performance is -15.11%.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) presented a corporate update at the Bank of America Merrill Lynch 2014 Healthcare Conference at the Encore at the Wynn in Las Vegas, NV. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) ended the last trading day at $13.72. Company weekly volatility is calculated as 7.58% and price to cash ratio as 5.70. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) showed a positive weekly performance of 13.29%.
NIOCORP DEVELOPMENTS (OTCQX:NIOBF) has added Scott Honan, who has more than 20 years of experience in the gold and rare earth industries, as VP of business development as the company ramps up development work on its Elk Creek niobium project. The stock jumped more than 14% on the news. NIOCORP DEVELOPMENTS (OTCMKTS:NIOBF) On last trading day company shares ended up $0.550.